# Center for Drug Evaluation

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/center-for-drug-evaluation
Canonical HTML page: https://gethealthbrief.com/entity/center-for-drug-evaluation

## Timeline

- **2026-03-24**: Phase III Initiation — First patient dosed at Peking Union Medical College Hospital in China.
- **2026-01-15**: Regulatory Designations — FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
- **2025-Q4**: Phase II Data Publication — Results showing efficacy without hormonal side effects published in The Lancet.

## Recent coverage (1 stories)

### Hope Medicine Doses First Phase III Patient for Non-Hormonal Endometriosis Drug
2026-03-25 12:12:33 · Sentiment: Positive · Impact: 7/10 · Sources: 10

Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Full story: https://gethealthbrief.com/story/hope-medicine-hmi115-phase-3-endometriosis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.